Abiomed Impella 2.5 Receives FDA Approval For Elective And Urgent High Risk Percutaneous Coronary Intervention (PCI) Procedures

Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news